Portfolio
About
News
Contact

A gallery of our work

MOA of anti-TNF agents

» Next
Previous »

This mechanism of action figure for the Clinical Therapeutics article “Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease” published in the New England Journal of Medicine shows how biologic agents (Infliximab, Adalimumab, Golimumab, and Certolizumab pegol) bind to tmTNF and sTNF thereby blocking the interaction between TNF molecules and the subsequent proinflammatory cell signaling.

Portfolio
About
News
Contacts

biomedart@haderermuller.com

Stay Connected

Legal Notice